Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20020 (
adenosine triphosphatase
)
3,299
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Inflammasomes activate caspase-1 for processing and secretion of the cytokines interleukin-1beta (IL-1beta) and IL-18.
Cryopyrin
/NALP3/NLRP3 is an essential component of inflammasomes triggered by microbial ligands, danger-associated molecular patterns (DAMPs), and crystals. Inappropriate
Cryopyrin
activity has been incriminated in the pathogenesis of gouty arthritis, Alzheimer's, and silicosis. Therefore, inhibitors of the Nalp3 inflammasome offer considerable therapeutic promise. In this study, we show that the type 2 diabetes drug glyburide prevented activation of the
Cryopyrin
inflammasome. Glyburide's cyclohexylurea group, which binds to
adenosine triphosphatase
(
ATP
)-sensitive K(+) (K(
ATP
)) channels for insulin secretion, is dispensable for inflammasome inhibition. Macrophages lacking K(
ATP
) subunits or ATP-binding cassette transporters also activate the
Cryopyrin
inflammasome normally. Glyburide analogues inhibit
ATP
- but not hypothermia-induced IL-1beta secretion from human monocytes expressing familial cold-associated autoinflammatory syndrome-associated
Cryopyrin
mutations, thus suggesting that inhibition occurs upstream of
Cryopyrin
. Concurrent with the role of
Cryopyrin
in endotoxemia, glyburide significantly delays lipopolysaccharide-induced lethality in mice. Therefore, glyburide is the first identified compound to prevent
Cryopyrin
activation and microbial ligand-, DAMP-, and crystal-induced IL-1beta secretion.
...
PMID:Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. 1980 29